Under antiviral treatment with lamivudine, the viraemia decreased to 3300 copies/ml within 2 weeks. Nevertheless, hepatic function did not recover, and the patient died 32 days after his admission.
Although reactivation of HBV in HBsAg-positive patients is a well-documented complication of cytotoxic treatments, 4, 5 to the best of our knowledge, this is the first case of HBV reactivation in a B-CLL patient after rituximab. Moreover, we recorded the presence of HBcAb and HBeAb associated with the negativity of HbsAg and HBsAb, indicating that these findings are a longlasting occult infection of a HBV variant strain. Given the high efficacy of prophylaxis with lamivudine, testing HBV DNA before immunosuppressive and cytotoxic treatments, including the anti-CD20 antibodies, should be recommended in order to identify HBV carriers among patients presenting HBcAb alone without any other serological HBV markers, since HBsAg routine tests may be unreliable in S-gene mutated variants. Notch signaling plays a key role in the cell fate decision at various differentiation branch points. 1 In mammals, it has been well recognized that the deregulated activation of Notch signaling leads to tumor development. 2 This concept is highlighted by a recent report demonstrating that as much as 60% of childhood T-cell acute lymphoblastic leukemia (T-ALL) has mutations in the Notch1 gene. 3 The resulting amino-acid changes have been found in the heterodimerization (HD) domains at the C-and N-termini of the extracellular and transmembrane subunits (HD EC and HDt domains), respectively, and the transcriptional activation (TA) and PEST domains at the cytoplasmic region of the transmembrane subunit. The former mutations are thought to reduce the affinity between the two subunits, which subsequently leads to ligand-independent g-cleavage of the Notch1 transmembrane subunit and production of an activated Notch1 intracellular domain. In the latter, insertion or deletion mutations introduce a premature stop codon that results in truncation of the PEST domain, which Extremely high frequency of activating mutations of the Notch1 gene gave us an idea that T-ALL is commonly dependent on abnormal Notch1 activation. Based on these findings, it has been postulated that g-secretase inhibitors, which are considered as a treatment modality against Alzheimer's disease, 4 could be useful as anti-T-ALL drugs.
While adult T-ALL has pathological characteristics common to childhood T-ALL, some differences have been recognized from both clinical observations 5 and molecular studies. 6 Therefore, it would be worthwhile to examine Notch1 mutations in adult T-ALL to gain insight into the entity and subclassification of T-ALL, based on the knowledge of exceptionally high frequency of Notch1 mutations in childhood T-ALL.
In the current study, we found that Notch1 mutations were frequent in both adult and childhood T-ALLs. In the 14 adult T-ALL samples, we found an in-frame 3-nucleotide deletion mutation in one and an in-frame 3-nucleotide insertion mutation in another in the HD EC domain. The former was described in the previous report as one of the 'hot spots' that leads to the deletion of 1579 V. In the latter (Figure 1, upper panel) , Gly was inserted between amino-acids 1597L and 1598S. Although the same mutation was not described in the previous report, these two residues are conserved among the vertebrate Notch1 gene products, and thus 1598 Ins G may also cause ligand-independent activation of Notch1. In the HDt domain, we found a missense mutation 1681I/N in one case, which was described in children ( Figure 1, middle panel) . In the TA domain, there was a mutation with a 3-nucleotide deletion and a 4-nucleotide insertion at the same position, resulting in a frame shift and a premature stop codon ( Figure 1, lower panel) . In the PEST domain, there was a mutation with a 5-nucleotide insertion, also resulting in a premature termination of translation. Both of these insertion mutations lead to truncation of the PEST domain.
Overall, we found five potentially activating mutations in five adult patients, among 14, with ages of 17, 19, 24, 31 and 37 years (summarized in Table 1 ). No sample showed mutations at both the HD and PEST domains, most likely because of the small sample number.
In 10 out of the 14 adults analyzed, we previously studied the deletion of CDKN2A antioncogene. Although homozygous deletion of this gene, which is known to be frequent in childhood T-ALL, was found in only one of these 10 cases, 7 we also found an activating Notch1 mutation in the HD domain in the same sample. From this observation, we can conclude that activating mutation of Notch1 gene and inactivation of CDKN2A gene, which are the most frequent abnormalities in T-ALL, are not likely to be mutually exclusive.
We also analyzed the Notch1 gene in 33 childhood T-ALL samples. We found 12, 3 and 2 mutations in the HD EC , HDt It is intriguing to consider g-secretase inhibitors as antileukemia agents, with Notch signaling being a new therapeutic target, since their efficacy is predicted and there are ongoing clinical trials of g-secretase inhibitors as anti-Alzheimer drugs. However, at least two issues must be considered further.
First, according to the previous report, many Notch1-mutated T-ALL cell lines are not likely to respond to g-secretase inhibitors, although some are definitely sensitive to these agents. Indeed, we found that g-secretase inhibitors that induce apoptosis in some T-ALL cell lines did not affect many Notch1-mutated T-ALL cell lines despite the fact that these g-secretase inhibitors unambiguously blocked the activation of Notch1 (data not shown). These findings indicate that Notch1 activation is not always required for the growth of T-ALL cell lines even if they have mutations. This may be due to additional mutations during establishment of the cell line or presense of Notch-independent cell growth machinery in T-ALL cells from patients. To see whether Notch signaling is a good therapeutic target, it is important to examine fresh T-ALL cells for frequency of responsiveness to g-secretase inhibitors.
Second, with the development of g-secretase inhibitors for the treatment of Alzheimer's disease, major effort has been made to find compounds that have less effect on Notch signaling. Indeed, it has been clearly shown that the administration of large amounts of Ly411575, a compound with a strong g-secretase inhibiting activity, to mice induces severe abnormalities in the immune system and digestive tract. 8 Therefore, it is unlikely that we can divert a g-secretase inhibitor that has been developed for treatment of Alzheimer's disease to an anti-T-ALL drug. We need a careful strategy to find g-secretase inhibitors or other Notch inhibitors that could be used for T-ALL and potentially other malignancies, with acceptable side effects due to the inhibition of Notch signaling, which is required for cell life physiologically. 1 Genetic abnormalities of the three genes RAS (15-20%), neurofibromatosis type I (NF1) (25%), and protein-tyrosine phosphatase, nonreceptor type 11 (PTPN11) (34%), all of which are positioned in the GM-CSF/Ras signal transduction pathway, have been implicated in the pathogenesis of JMML. [2] [3] [4] One of these genetic abnormalities is observed in 75% of JMML patients, leaving 25% of the reported cases in which a specific mutation has yet to be detected. Recent reports described an acquired mutation of the tyrosine kinase JAK2 gene that has been found in human myeloproliferative disorders, and the single-point mutation (Val617Phe) in exon 12 was identified. [5] [6] [7] Several data demonstrate that JAK2 is physically associated with the GM-CSFRb chain, becoming activated upon challenge of myeloid cells with GM-CSF. 8 To clarify the involvement of JAK2 in the pathogenesis of JMML, we searched for mutations in the JAK2 gene in five JMML patients.
The diagnosis of JMML for each patient was confirmed according to diagnostic criteria agreed upon by the International JMML Working Group. 1 Genomic DNA was extracted from patients' bone marrow cells, and the human JAK2 exon 12 was
